Skip to main content
46°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc. Common Shares
(NY:
CYBN
)
7.240
+0.220 (+3.13%)
Streaming Delayed Price
Updated: 11:35 AM EDT, May 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc. Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Analyst Expectations for Cybin's Future
November 17, 2023
Via
Benzinga
Expedia To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Friday
November 17, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event
November 16, 2023
Via
Investor Brand Network
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
November 16, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
November 15, 2023
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023.
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
November 15, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
November 15, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
November 14, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
November 14, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
November 10, 2023
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new...
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
November 10, 2023
Via
Investor Brand Network
Cybin Announces up to US$64 Million Offering of Units
November 10, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
November 03, 2023
Via
Investor Brand Network
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
November 03, 2023
From
Cybin Inc.
Via
Business Wire
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
November 01, 2023
Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003
Via
Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
November 01, 2023
Via
Investor Brand Network
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
November 01, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
October 31, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
October 29, 2023
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
October 26, 2023
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
October 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
October 26, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
October 25, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
October 25, 2023
From
Cybin Inc.
Via
Business Wire
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
October 23, 2023
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
October 23, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
October 23, 2023
From
Cybin Inc.
Via
Business Wire
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
October 22, 2023
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.